Phase 1 trial of STX-0712 for rare leukemia CMML doses first patient
The first patient has been dosed in a Phase 1 clinical trial evaluating the safety and early efficacy of STX-0712 in people with resistant or…
The first patient has been dosed in a Phase 1 clinical trial evaluating the safety and early efficacy of STX-0712 in people with resistant or…
A new approach in immunotherapy that can safely boost the body’s immune response has shown promise in hard-to-treat tumors like pancreatic cancers, a study…
CAN-2409 (aglatimagene besadenovec), Candel Therapeutics‘ investigational immunotherapy, was safe and demonstrated potential survival benefits in patients with high-grade glioma, an aggressive type of…